AHA Updates Secondary Prevention Guidelines After Bypass Surgery
The American Heart Association's 2026 update outlines evidence-based strategies to slow disease progression and protect grafts after CABG.
20 articles
The American Heart Association's 2026 update outlines evidence-based strategies to slow disease progression and protect grafts after CABG.
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.
A landmark AHA scientific statement tackles inconsistent cardiovascular safety reporting in oncology trials with a unified framework.
A translational review outlines how stem cell technologies may finally make hepatocyte-based liver therapies clinically viable.
A Cochrane meta-analysis of 11 RCTs finds very low-certainty evidence that liver support systems neither reduce mortality nor improve key outcomes in ALF.
A Cochrane review of 4 RCTs finds no reliable evidence that adding endovascular stenting to medical therapy prevents stroke or death in vertebral artery stenosis.
Scientists propose space environments as unique models for studying accelerated aging mechanisms and potential interventions.
A Cochrane review of 21 RCTs finds remote pharmacist care may improve adherence and lower blood pressure in NCD patients.
Burke and Noakes reach surprising common ground on fueling endurance sport, while key disagreements remain unresolved.
A new AHA scientific statement outlines evidence-based strategies to optimize heart failure care for older adults navigating frailty, polypharmacy, and multimorbidity.
A major review in Nature Medicine explores how CAR cell therapies may achieve deep immune 'reset' in autoimmune diseases by depleting pathogenic B cells.
A Circulation review from Harvard proposes the 'target trial framework' to improve how observational data is used to assess cardiovascular device safety and effectiveness.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.
New review explores how 3D organoids and bioengineered niches are revolutionizing tumor research and treatment development.
A major Lancet review reveals 27 million women suffer postpartum haemorrhage annually, costing $10.4B and claiming 43,000 lives โ with most deaths preventable.
A new review links adult cholestasis to pediatric genetic syndromes, opening doors to targeted therapies including novel bile acid transport inhibitors.
A new perspective in Nature Cancer outlines how genetically engineered bacteria can target and destroy tumors from within.
A 2026 Cochrane update finds most evidence on turning frequency and position for pressure injury prevention remains very low certainty.
Expert reviews compare top CGMs for longevity use, but evidence for healthy adults remains limited. Here's what you need to know.
Bacteriophages transferred during FMT may drive horizontal gene transfer, altering microbial function and antibiotic resistance in ways science has largely ignored.